| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.
|
JAMA
|
1998
|
5.09
|
|
2
|
A prospective, randomized trial comparing laparoscopic versus conventional techniques in colorectal cancer surgery: a preliminary report.
|
J Am Coll Surg
|
1998
|
3.52
|
|
3
|
Cervical cancer screening by simple visual inspection after acetic acid.
|
Obstet Gynecol
|
2001
|
2.02
|
|
4
|
Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia.
|
Gynecol Oncol
|
2001
|
1.93
|
|
5
|
Clinical features of hypersensitivity reactions to carboplatin.
|
J Clin Oncol
|
1999
|
1.87
|
|
6
|
Prospective, randomized trial comparing laparoscopic vs. conventional surgery for refractory ileocolic Crohn's disease.
|
Dis Colon Rectum
|
2001
|
1.82
|
|
7
|
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.
|
Ann Oncol
|
2007
|
1.39
|
|
8
|
Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma.
|
J Clin Oncol
|
1997
|
1.28
|
|
9
|
Importance of continued testicular suppression in hormone-refractory prostate cancer.
|
J Clin Oncol
|
1993
|
1.18
|
|
10
|
Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial.
|
J Clin Oncol
|
1995
|
1.16
|
|
11
|
Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
|
Clin Cancer Res
|
2001
|
1.14
|
|
12
|
Temsirolimus in VEGF-refractory metastatic renal cell carcinoma.
|
Ann Oncol
|
2010
|
1.10
|
|
13
|
Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases.
|
Gynecol Oncol
|
2001
|
1.00
|
|
14
|
Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis.
|
Adv Exp Med Biol
|
1999
|
0.97
|
|
15
|
Decreased serum phosphate levels after high-dose estrogens in metastatic prostate cancer. Possible implications.
|
Am J Med
|
1984
|
0.95
|
|
16
|
Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis.
|
Clin Cancer Res
|
2000
|
0.95
|
|
17
|
The impact of interleukin-2 on survival in renal cancer: a multivariate analysis.
|
Cancer Biother
|
1993
|
0.93
|
|
18
|
Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma.
|
Surgery
|
1991
|
0.93
|
|
19
|
Interferon-alpha and survival in renal cell cancer.
|
Br J Urol
|
1995
|
0.92
|
|
20
|
G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer.
|
Oncogene
|
2011
|
0.89
|
|
21
|
Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
|
J Clin Oncol
|
1994
|
0.88
|
|
22
|
Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
|
Clin Cancer Res
|
1998
|
0.88
|
|
23
|
Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas.
|
Invest New Drugs
|
2000
|
0.86
|
|
24
|
Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
|
J Urol
|
2009
|
0.85
|
|
25
|
Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.
|
Ann Oncol
|
2010
|
0.83
|
|
26
|
Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma.
|
Ann Oncol
|
2006
|
0.83
|
|
27
|
A phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell carcinoma.
|
Invest New Drugs
|
2002
|
0.81
|
|
28
|
Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response.
|
J Immunother
|
1997
|
0.80
|
|
29
|
The colposcopic impression. Is it influenced by the colposcopist's knowledge of the findings on the referral Papanicolaou smear?
|
J Reprod Med
|
2001
|
0.80
|
|
30
|
Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings.
|
Clin Cancer Res
|
1996
|
0.80
|
|
31
|
A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer.
|
Invest New Drugs
|
1996
|
0.79
|
|
32
|
Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12.
|
J Immunother
|
1999
|
0.78
|
|
33
|
A phase II trial of melphalan or thioguanine in the treatment of patients with advanced renal cell cancer.
|
Urol Oncol
|
2011
|
0.77
|
|
34
|
Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.
|
Invest New Drugs
|
2008
|
0.77
|
|
35
|
5-Azacytidine (NSC 102816) in refractory germ cell tumors. A phase II trial of the Eastern Cooperative Oncology Group.
|
Invest New Drugs
|
1994
|
0.76
|
|
36
|
GM-CSF safety and effects in the management of advanced/refractory multiple myeloma patients: a phase I trial.
|
J Cancer Res Clin Oncol
|
2001
|
0.76
|
|
37
|
Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens.
|
Cancer
|
1982
|
0.76
|
|
38
|
Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer.
|
Invest New Drugs
|
1999
|
0.76
|
|
39
|
An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma.
|
Cancer
|
1994
|
0.76
|
|
40
|
Phase II evaluation of VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study.
|
Cancer Treat Rep
|
1982
|
0.75
|
|
41
|
Phase II trial of misonidazole (MISO) and cyclophosphamide (CYC) in metastatic renal cell carcinoma.
|
Int J Radiat Oncol Biol Phys
|
1986
|
0.75
|
|
42
|
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
|
J Cancer Res Clin Oncol
|
2001
|
0.75
|
|
43
|
Evaluation of carboplatin (NSC 241240) in patients with recurrent or metastatic renal cell carcinoma.
|
Invest New Drugs
|
1990
|
0.75
|
|
44
|
Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology Group.
|
J Urol
|
1990
|
0.75
|
|
45
|
Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor.
|
Am J Clin Oncol
|
2001
|
0.75
|
|
46
|
Does MCAT predict clinical performance?
|
J S C Med Assoc
|
1979
|
0.75
|
|
47
|
Carboplatin in advanced, refractory germ cell neoplasms: a phase II Eastern Cooperative Oncology Group Study.
|
Cancer Treat Rep
|
1987
|
0.75
|
|
48
|
Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.
|
J Clin Oncol
|
1991
|
0.75
|
|
49
|
Treatment of metastatic prostate cancer. An analysis of response criteria in patients with measurable soft tissue disease.
|
Cancer
|
1984
|
0.75
|
|
50
|
Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: clinical and biologic effects.
|
J Immunother
|
2001
|
0.75
|
|
51
|
Trimetrexate in advanced renal cell carcinoma. An ECOG phase II trial.
|
Invest New Drugs
|
1992
|
0.75
|